#BioCryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

BioCryst Pharmaceuticals Acquires Astria Pharmaceuticals Today, January 23, 2026, BioCryst Pharmaceuticals, Inc. ( BCRX ) announced it completed acquisition of Astria Therapeutics, Inc. , initially an...

P

Prohost Biotech

Jan 26, 2026

1m

2

News & Comments

Dyax Acquisition and Biocryst Future

- Shire to Acquire Dyax for $5.9million and some possible extras. - Angioedema market has treatments for attacks, but not prophylactic products for the prevention of HAE attacks. - A primary reason f...

P

Prohost Biotech

Nov 3, 2015

Prohost Letter #386

Prohost Letter #386 An Evaluation of Prohost Picks and Some Other Interesting Biotechnology Companies (Part 2) (Continued from Previous Prohost Letter #385) See Page Listening to Top-tier biotech firm...

P

Prohost Biotech

Nov 2, 2015

Prohost Letter #383

Prohost Letter #383 The Market - Recent tails about the market and the biotech sector are true thrillers. By true we mean no-fiction. The accounts lack common sense. Professionals' interpretations of...

P

Prohost Biotech

Sep 25, 2015

Prohost Letter #381

Prohost Letter #381 QUARTERLY FINANCIAL RESULTS IN THE BIOTECH SECTOR Investors Concerns, Excitement and Expectations (Part 3) For the past quarter of a century we spent focusing on the biotech sector...

P

Prohost Biotech

Jul 31, 2015

1m

2

News & Comments

Unearthing Dynavax Treasures Has Nothing to Do with Greece Troubles

Today it is Greece. What About Tomorrow? Can Greece's crisis devastate the biotech sector? No sane individual would think so and the hysteria cannot be called other than what it is. The biotech sector...

P

Prohost Biotech

Jun 29, 2015

8m

4

News & Comments

Biocryst: A Major Game Changing Agreement

On Thursday June 18, 2015, we posted an article under “Today’s Highlights” at the Prohost website about an important agreement Biocryst Pharmaceuticals (BCRX) signed with CSL We expect the agreement t...

P

Prohost Biotech

Jun 22, 2015

Prohost Portfolio Stocks Escaping Friday Intended Selloff

Although still a profit taking day, some of the following firms rallied, others did well and some escaped the selloff. Stocks That Escaped Friday’s Profit Taking AMGN: The stock remained positive, clo...

P

Prohost Biotech

Jun 19, 2015

Biocryst Good News and Receptos Rally

Biocryst (BCRX) licensed Rapivab (peramivir injection) for the treatment of influenza, to CSL Limited, a global biopharmaceutical company based in Australia. Rapivab is an intravenous (I.V.) viral neu...

P

Prohost Biotech

Jun 18, 2015

Amgen and Regeneron Rallies. See Other Outperforming Picks

The talk of the town now is about the anti-LDL drugs Repatha developed by Amgen (AMGN) and Praluent developed by Sanofi and Regeneron (REGN) ; both are PCSK9 inhibitors, a new class of anti-lipemic dr...

P

Prohost Biotech

Mar 17, 2015

Biocryst and Sequenom News Before the Storm

Biocryst Pharmaceutical (BCRX): The FDA has granted Fast Track designation for the firm’s drug BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical deve...

P

Prohost Biotech

Jan 26, 2015

Monday, January 5, 2015: Outperforming and Positive Performing Picks

OUR OUTPERFORMING PICKS ON MONDAY 5/1/2015 ISIS: Closed at $68.17 UP $6.60 J&J is licensing three programs for autoimmune diseases from Isi...

P

Prohost Biotech

Jan 6, 2015

The Danger Gilead Is Facing

Gilead A War and a Possible SellOff? We are witnessing an expected exaggerated selloff of GILD following news that Express Script Holding Co. will make AbbVie HCV drug the exclusive option for patien...

P

Prohost Biotech

Dec 22, 2014

Incyte Drug Baricitinib Has Promising Results in Rheumatoid Arthritis and More News

In December 2009, Lilly (LLY) and Incyte (INCY) announced an exclusive worldwide license and collaboration agreement for the development and commercialization ofbaricitinib and certain follow-on compo...

P

Prohost Biotech

Dec 11, 2014

Important News About Two Deadly Diseases and an Important Patent

What’s Going On Now? OF THE EFFORTS TO TREAT ALS Autologus Stem Cells BrainStorm Cell Therapeutics Inc (BCLI): The FDA has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic l...

P

Prohost Biotech

Oct 7, 2014

Prohost Letter #370

...

P

Prohost Biotech

Oct 6, 2014

The RNAi Group: Tekmira Rallies and More

Three firms we have already picked and added to Prohost portfolios are rallying today. Indeed.Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX) were the first to cross investors’ minds when ebola’s d...

P

Prohost Biotech

Oct 1, 2014

Biotechnology Good News Eclipsed by Unwarranted Bad Market

The Biotechnology Sector has plenty of good news this week. Unfortunately, the good news from the scientifically sound biotechnology firms was overshadowed yesterday by the stock market’s acute, proba...

P

Prohost Biotech

Sep 26, 2014

Prohost Letter #369

...

P

Prohost Biotech

Sep 23, 2014

Biocryst Is Moving Forward. Our BCRX Targets are Unchanged

BioCryst (BCRX) is one of our recently picked biotech stocks. This firm has just announced that the National Institute Of Allergy and Infectious Diseases (NIAID) has exercised additional options to co...

P

Prohost Biotech

Aug 13, 2014

1m

2